Study finds potential key to immune suppression in cancer

January 19, 2012

In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) – cells that play a major role in cancer-related immune suppression – dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.

Their study appeared in a recent issue of Cancer Research, published by the American Association for Cancer Research.

According to the authors, it has been established that inadequate immune response in cancer is a critical element in tumor escape, and that myeloid-derived (MDSCs) – cells that which normally keep the immune system in check and prevent it from attacking otherwise healthy tissue – can suppress the anti-tumor response and play a major role in tumor associated immune abnormalities.

In addition, research has shown that MDSCs block other cells (such as CD 8 "killer" T cells) from binding with proteins that identify foreign antigens on the surface of unhealthy cancer cells and, in doing so, mark them as targets.

"To better understand the biology of immune defects in cancer, our study investigated the antigen-specific nature of MDSCs and their ability to cause antigen specific CD4 T cell tolerance," said study corresponding author Dmitry Gabrilovich, M.D., Ph.D., who holds the Robert Rothman Endowed Chair in Cancer Research at Moffitt and whose research focus is on immunology. "We found that antigen specific were able to dramatically enhance the immune suppressive activity of MDSC by converting them into powerful non-specific suppressors. But, to our surprise, we did not see the same response from CD8 T cells."

The researchers initially investigated several tumors modeled in mice but focused on two models of particular interest.

They reported that major histocompatability complex (MHC) class II molecules – found only on a few specialized cell types – played a role in this conversion to MDSC-mediated suppression when MHC class II and MDSC "cross-linked" through cell-to-cell contact. The effect, however, was dependent on the expression of MHC class II.

"This study showed for the first time that activated antigen-specific T-cells can potentiate the immune suppressive activity of MDSC by converting these to non-specific suppressors and, thus, limit the ability of the host to mount a potent ," concluded the authors.

The researchers suggested that their study might shed light on a mechanism that may act as a "negative feedback loop" aimed at controlling responses that become "dysregulated" in cancer.

Explore further: Immune cells link pregnancy and tumor spread

Related Stories

Immune cells link pregnancy and tumor spread

June 6, 2011

Individuals with cancer often do not die as a result of their initial tumor but as a result of tumors at distant sites that are derived from the initial tumor. Pregnancy is a condition that seems to be permissive for tumor ...

Using Viagra to combat malignant melanoma

November 8, 2011

Many tumors cause chronic inflammations, which, in their turn, suppress specific attacks against the tumor by the immune system. Scientists at the German Cancer Research Center and Medical Faculty Mannheim at Heidelberg University ...

Recommended for you

Epigenomic changes are key to innate immunological memory

August 31, 2015

A research team led by Keisuke Yoshida and Shunsuke Ishii of the RIKEN Molecular Genetics Laboratory has revealed that epigenomic changes induced by pathogen infections, mediated by a transcription factor called ATF7, are ...

Team finds early inflammatory response paralyzes T cells

August 18, 2015

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help ...

SIV shrugs off antibodies in vaccinated monkeys

August 11, 2015

New research on monkeys vaccinated against HIV's relative SIV calls into question an idea that has driven AIDS vaccine work for years. The assumption: a protective vaccine only needs to stimulate moderate levels of antibodies ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.